These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

215 related items for PubMed ID: 14639675

  • 1. Randomized, double-blind, 3-month parallel study of the effects of pramipexole, pergolide, and placebo on Parkinsonian tremor.
    Navan P, Findley LJ, Jeffs JA, Pearce RK, Bain PG.
    Mov Disord; 2003 Nov; 18(11):1324-31. PubMed ID: 14639675
    [Abstract] [Full Text] [Related]

  • 2. Double-blind, single-dose, cross-over study of the effects of pramipexole, pergolide, and placebo on rest tremor and UPDRS part III in Parkinson's disease.
    Navan P, Findley LJ, Jeffs JA, Pearce RK, Bain PG.
    Mov Disord; 2003 Feb; 18(2):176-80. PubMed ID: 12539211
    [Abstract] [Full Text] [Related]

  • 3. Pramipexole, a nonergot dopamine agonist, is effective against rest tremor in intermediate to advanced Parkinson's disease.
    Künig G, Pogarell O, Möller JC, Delf M, Oertel WH.
    Clin Neuropharmacol; 1999 Feb; 22(5):301-5. PubMed ID: 10516884
    [Abstract] [Full Text] [Related]

  • 4. A randomly assigned double-blind cross-over study examining the relative anti-parkinsonian tremor effects of pramipexole and pergolide.
    Navan P, Findley LJ, Undy MB, Pearce RK, Bain PG.
    Eur J Neurol; 2005 Jan; 12(1):1-8. PubMed ID: 15613140
    [Abstract] [Full Text] [Related]

  • 5. Conversion from dopamine agonists to pramipexole. An open-label trial in 227 patients with advanced Parkinson's disease.
    Linazasoro G, Spanish Dopamine Agonists Study Group.
    J Neurol; 2004 Mar; 251(3):335-9. PubMed ID: 15015015
    [Abstract] [Full Text] [Related]

  • 6. Long-term efficacy and safety of pramipexole in advanced Parkinson's disease: results from a European multicenter trial.
    Möller JC, Oertel WH, Köster J, Pezzoli G, Provinciali L.
    Mov Disord; 2005 May; 20(5):602-10. PubMed ID: 15726540
    [Abstract] [Full Text] [Related]

  • 7. High doses of pergolide improve clinical global impression in advanced Parkinson's disease:- a preliminary open label study.
    Arnold G, Gasser T, Storch A, Lipp A, Kupsch A, Hundemer HP, Schwarz J.
    Arch Gerontol Geriatr; 2005 May; 41(3):239-53. PubMed ID: 16029905
    [Abstract] [Full Text] [Related]

  • 8. Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial.
    Holloway RG, Shoulson I, Fahn S, Kieburtz K, Lang A, Marek K, McDermott M, Seibyl J, Weiner W, Musch B, Kamp C, Welsh M, Shinaman A, Pahwa R, Barclay L, Hubble J, LeWitt P, Miyasaki J, Suchowersky O, Stacy M, Russell DS, Ford B, Hammerstad J, Riley D, Standaert D, Wooten F, Factor S, Jankovic J, Atassi F, Kurlan R, Panisset M, Rajput A, Rodnitzky R, Shults C, Petsinger G, Waters C, Pfeiffer R, Biglan K, Borchert L, Montgomery A, Sutherland L, Weeks C, DeAngelis M, Sime E, Wood S, Pantella C, Harrigan M, Fussell B, Dillon S, Alexander-Brown B, Rainey P, Tennis M, Rost-Ruffner E, Brown D, Evans S, Berry D, Hall J, Shirley T, Dobson J, Fontaine D, Pfeiffer B, Brocht A, Bennett S, Daigneault S, Hodgeman K, O'Connell C, Ross T, Richard K, Watts A, Parkinson Study Group.
    Arch Neurol; 2004 Jul; 61(7):1044-53. PubMed ID: 15262734
    [Abstract] [Full Text] [Related]

  • 9. Trial of subtherapeutic pergolide in de novo Parkinson's disease.
    Grosset K, Grosset D, Lees A, Parkinson's Disease Research Group of the United Kingdom.
    Mov Disord; 2005 Mar; 20(3):363-6. PubMed ID: 15580607
    [Abstract] [Full Text] [Related]

  • 10. The effect of pramipexole on mood and motivational symptoms in Parkinson's disease: a meta-analysis of placebo-controlled studies.
    Leentjens AF, Koester J, Fruh B, Shephard DT, Barone P, Houben JJ.
    Clin Ther; 2009 Jan; 31(1):89-98. PubMed ID: 19243709
    [Abstract] [Full Text] [Related]

  • 11. Randomized, double-blind, multicenter evaluation of pramipexole extended release once daily in early Parkinson's disease.
    Hauser RA, Schapira AH, Rascol O, Barone P, Mizuno Y, Salin L, Haaksma M, Juhel N, Poewe W.
    Mov Disord; 2010 Nov 15; 25(15):2542-9. PubMed ID: 20669317
    [Abstract] [Full Text] [Related]

  • 12. Extended-release pramipexole in early Parkinson disease: a 33-week randomized controlled trial.
    Poewe W, Rascol O, Barone P, Hauser RA, Mizuno Y, Haaksma M, Salin L, Juhel N, Schapira AH, Pramipexole ER Studies Group.
    Neurology; 2011 Aug 23; 77(8):759-66. PubMed ID: 21832218
    [Abstract] [Full Text] [Related]

  • 13. Switching from pergolide to pramipexole in patients with Parkinson's disease.
    Hanna PA, Ratkos L, Ondo WG, Jankovic J.
    J Neural Transm (Vienna); 2001 Aug 23; 108(1):63-70. PubMed ID: 11261747
    [Abstract] [Full Text] [Related]

  • 14. A randomized, double-blind, placebo-controlled trial of pramipexole, a dopamine agonist, in patients with fibromyalgia receiving concomitant medications.
    Holman AJ, Myers RR.
    Arthritis Rheum; 2005 Aug 23; 52(8):2495-505. PubMed ID: 16052595
    [Abstract] [Full Text] [Related]

  • 15. [The effectiveness and tolerance of piribedil as adjunct therapy to levodopa in patients with Parkinson's disease: a nine month follow up].
    Salazar Tortolero G, Wix Ramos R, Salazar Aladrén P, Jiménez León JC.
    Rev Neurol; 2005 Aug 23; 38(8):715-9. PubMed ID: 15122540
    [Abstract] [Full Text] [Related]

  • 16. Dopamine and cognitive functioning in de novo subjects with Parkinson's disease: effects of pramipexole and pergolide on working memory.
    Costa A, Peppe A, Dell'Agnello G, Caltagirone C, Carlesimo GA.
    Neuropsychologia; 2009 Apr 23; 47(5):1374-81. PubMed ID: 19428401
    [Abstract] [Full Text] [Related]

  • 17. The use of pramipexole, a novel dopamine (DA) agonist, in advanced Parkinson's disease.
    Molho ES, Factor SA, Weiner WJ, Sanchez-Ramos JR, Singer C, Shulman L, Brown D, Sheldon C.
    J Neural Transm Suppl; 1995 Apr 23; 45():225-30. PubMed ID: 8748629
    [Abstract] [Full Text] [Related]

  • 18. Rationale for delayed-start study of pramipexole in Parkinson's disease: the PROUD study.
    Schapira AH, Albrecht S, Barone P, Comella CL, McDermott MP, Mizuno Y, Poewe W, Rascol O, Marek K.
    Mov Disord; 2010 Aug 15; 25(11):1627-32. PubMed ID: 20544810
    [Abstract] [Full Text] [Related]

  • 19. Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial.
    Barone P, Poewe W, Albrecht S, Debieuvre C, Massey D, Rascol O, Tolosa E, Weintraub D.
    Lancet Neurol; 2010 Jun 15; 9(6):573-80. PubMed ID: 20452823
    [Abstract] [Full Text] [Related]

  • 20. Twice-daily, low-dose pramipexole in early Parkinson's disease: a randomized, placebo-controlled trial.
    Kieburtz K, Parkinson Study Group PramiBID Investigators.
    Mov Disord; 2011 Jan 15; 26(1):37-44. PubMed ID: 20925067
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.